Analysts expect Kura Oncology to report Q3 2026 revenue of approximately $24.86 million and a consensus EPS loss of $0.83, with the current stock price of $6.80 trading significantly below the average analyst target of $24.00.
Investors are primarily focused on the commercial launch momentum of KOMZIFTI (ziftomenib), the company’s recently approved menin inhibitor for NPM1-mutated acute myeloid leukemia.
Management’s execution in scaling product sales while managing cash burn is a critical focal point, especially given the current cash runway supported by the Kyowa Kirin global partnership.
Additionally, the market is awaiting updates on Phase 3 trial enrollments and potential pipeline synergies within the company's precision oncology portfolio.